Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Calcific uremic arteriolopathy, also known as calciphylaxis, is a rare, oftentimes fatal complication usually associated with end stage renal disease. It is characterized by skin ulceration and necrosis, primarily in the lower extremities leading to significant pain for afflicted patients. There are a variety of medications associated with increased risk for developing calciphylaxis. Calcium supplements, calcium-based phosphate binders, and active Vitamin D inherently increase the available calcium for deposition, thus explaining their association. Other associated medications include corticosteroids, iron, teriperitide, and trauma related to subcutaneous insulin injections. Warfarin is one medication that has gained increasing awareness as a potential contributor to calciphylaxis, with multiple studies. This report studies the global market for calciphylaxis treatment in terms of revenue (USD million) from 2019 to 2024.
The global calciphylaxis treatment market has gained profitable growth owing increasing patients’ population with renal failure. The market is further boosted by technological advancements in calciphylaxis treatments. Moreover, the market is expected to show robust growth during the forecast period due to surging government spending on pharmaceutical R&D in emerging nations. Increasing use of warfarin therapy and favourable reimbursement scenario are further expected to propel this market growth. However, the global calciphylaxis treatment market is hindered by higher cost of existing treatment.
The report analyses the global calciphylaxis treatment market, based on diagnosis, treatment, end user and geography.
The market is segmented into various diagnosis, such as deep skin biopsies, which includes shave biopsy, punch biopsy, and excisional biopsy; blood tests, which includes serum parathormone levels, blood glucose levels, BUN (blood urea nitrogen), calcium levels, and others; and imaging including magnetic resonance imaging (MRI), CT scan, ultrasound, and others. Among these, the imaging segment dominated the market in 2017 and is expected to grow at a lucrative growth rate during the forecast period, due to its use in the diagnosis of calciphylaxis.
The calciphylaxis treatment is classified into various treatments such as intensive wound care, medication, therapy and clot-dissolving. The medication segment is further segmented into cinacalcet, sodium thiosulfate, steroids, and bisphosphonates. In 2017, the therapy dominated the global market, owing to its increasing use in the calciphylaxis treatment.
The market is segmented into various end users, which hospitals, clinics, medical research centers and academic institutes. Among these, the hospitals segment dominated the market in 2017 and is expected to grow at a lucrative growth rate during the forecast period, due to surging number of hospitals diagnosing calciphylaxis treatment.
By geography, the global calciphylaxis treatment market is segmented into North America, Europe, Asia Pacific and Rest of the World. North America dominated the global calciphylaxis treatment market in 2017, due to advanced hospitals infrastructures, and availability of skilled healthcare professionals. Presence of strong economic condition and huge development in the healthcare domain are further fuelling the market growth. Moreover, Asia Pacific is the anticipated to grow at a fastest growth rate during the forecast period 2019 to 2024 among other regions. The higher rate of the growth is fuelled by increasing emphasis on rapid diagnosis and treatment of calciphylaxis, changing lifestyle and increasing prevalence of cancer among geriatric population.
The demand for calciphylaxis treatment market is gauzed by market attractiveness tool and company market share. The key players of global calciphylaxis treatment market include Amgen Inc., Smith & Nephew Plc, Medtronics, 3M, BSN Medical and ConvaTec Inc. among others. Strategies such as product innovation and collaborations are adopted by global players as well as regional players, to maintain the product superiority, thus interpreting market sustainability.
The global calciphylaxis treatment market is segmented based on diagnosis, treatment, end users and geography. The market is segmented into various diagnosis, such as deep skin biopsies, which includes shave biopsy, punch biopsy, and excisional biopsy; blood tests, which includes serum parathormone levels, blood glucose levels, BUN (blood urea nitrogen), calcium levels, and others; and imaging including magnetic resonance imaging (MRI), CT scan, ultrasound, and others.
The calciphylaxis treatment is classified into various treatments such as intensive wound care, medication, therapy and clot-dissolving. The medication segment is further segmented into cinacalcet, sodium thiosulfate, steroids, and bisphosphonates. In 2017, the therapy dominated the global market, owing to its increasing use in the calciphylaxis treatment.
The market is segmented into various end users, which hospitals, clinics, medical research centers and academic institutes. Among these, the hospitals segment dominated the market in 2017 and is expected to grow at a lucrative growth rate during the forecast period, due to surging number of hospitals diagnosing calciphylaxis treatment.
By geography, the global calciphylaxis treatment market is segmented into North America, Europe, Asia Pacific and Rest of the World. North America dominated the global calciphylaxis treatment market in 2017, due to advanced hospitals infrastructures, and availability of skilled healthcare professionals.
Why to buy this report:
